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Abstract
Background: In unclear pancreatic lesions, a tissue sample can confirm or exclude the suspected diagnosis and help to
provide an optimal treatment strategy to each patient. To date only one small study reported on the outcome of
computed tomography (CT) fluoroscopy-guided biopsies of the pancreas.
Purpose: To evaluate technical success and diagnostic rate of all CT fluoroscopy-guided core biopsies of the pancreas
performed in a single university center during a 10-year period.
Material and Methods: In this retrospective study we included all patients who underwent a CT fluoroscopy-guided
biopsy of a pancreatic mass at our comprehensive cancer center between 2005 and 2014. All interventions were
performed under local anesthesia on a 16-row or 128-row CT scanner. Technical success and diagnostic rates as well
as complications and effective patient radiation dose were analyzed.
Results: One hundred and one patients (54 women; mean age, 63.9 12.6 years) underwent a total of 104 CT
fluoroscopy-guided biopsies of the pancreas. Ninety-eight of 104 interventions (94.2%) could be performed with tech-
nical success and at least one tissue sample could be obtained. In 88 of these 98 samples, a definitive pathological
diagnosis, consistent with clinical success could be achieved (89.8%). Overall 19 minor and three major complications
occurred during the intra- or 30-day post-interventional period and all other interventions could be performed without
complications; there was no death attributable to the intervention.
Conclusion: CT fluoroscopy-guided biopsy of pancreatic lesions is an effective procedure characterized by a low major
complication and a high diagnostic rate.
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Introduction
Pancreatic adenocarcinoma is an aggressive disease
typically presenting as unresectable at the time of first
diagnosis, with a median survival of 6–10 months (1).
Therefore, solid pancreatic masses should be
investigated carefully to exclude or confirm pancreatic
malignancy (2). However, standard cross-sectional
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imaging modalities do not always allow for a definitive
diagnosis. Uncharacteristic findings make it difficult to
differentiate adenocarcinoma from other causes of focal
pancreatic lesions or benign inflammatory conditions
(3). In such cases, histopathological analysis of a
tissue sample can confirm or exclude the suspected
diagnosis and help to provide an optimal treatment
strategy to each patient. In addition, for an accurate
planning of chemotherapy regimens, a definitive histo-
pathological workup is necessary (4). However, it may
be technically difficult to obtain tumor tissue for a
pathological diagnosis before treatment initiation
specifically in patients with an unresectable, locally
advanced pancreatic adenocarcinoma (without distant
metastases). A pre-treatment tumor biopsy is recom-
mended by several international guidelines and medical
oncologists routinely insist on a histological confirm-
ation before initiation of chemo- or radiotherapy.
This issue recently became even more important with
an increase in neoadjuvant trials focusing on patients
with resectable (often small tumors), borderline resect-
able, and locally advanced pancreatic cancer. The vast
majority of these neoadjuvant studies require a con-
firmation of adenocarcinoma as an inclusion criterion
and the inability of confirming the diagnosis by hist-
ology (or cytology) is thought to be one major barrier
for trial recruitment (5).
Pancreatic fine-needle aspiration or core-needle
biopsy can be performed either in an open-surgical
manner or under image guidance using ultrasound,
endoscopic ultrasound, or computed tomography
(CT) (6). Several studies reported the results of ultra-
sound- or endoscopy-guided biopsies (7,8). In contrast,
only few studies focused on the outcome of CT-guided
biopsies (8–12). Most of these studies used sequential
CT guidance and not CT fluoroscopy. To the best of
our knowledge only one relatively small study from
2002 covered the use of CT fluoroscopy for guidance
of pancreatic true-cut biopsies (13). In contrast to
sequential CT guidance, CT fluoroscopy-guided inter-
ventions can be performed faster, safer, and with a
lower effective patient radiation dose (14,15).
Therefore, the aim of this study was to evaluate
technical success and diagnostic accuracy of all CT
fluoroscopy-guided true-cut biopsies of the pancreas
performed at our cancer center during a 10-year
period. Additionally, complications and effective radi-
ation dose are reported.
Material and Methods
All procedures performed in this retrospective study
were in accordance with the institutional ethic commit-
tee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. All
patients gave written informed consent for the proced-
ures of this study.
Patients
In our retrospective single-center study, all patients
were included who had undergone CT fluoroscopy-
guided pancreatic true-cut biopsy between January
2005 and June 2014. Patients were selected by screening
the RIS (Radiological Information System) for proced-
ures encoded as ‘‘CT-guided biopsy of the pancreas.’’
After anonymization of all patient information, data
collection was performed.
This study only includes true-cut biopsies taken for
histological examination. Patients who were punctured
in the pancreatic region for placement of drainage were
excluded from this analysis. In all cases CT, magnetic
resonance imaging (MRI) and/or ultrasound had been
performed prior to the intervention. A multidisciplin-
ary team of oncologists, gastroenterologists, radiation
oncologists, general surgeons, and interventional radi-
ologists discussed clinical indication for the biopsies
(e.g. suspicion of a locally advanced or metastatic pan-
creatic tumor by imaging criteria, neoadjuvant treat-
ment in borderline resectable tumors). We also
documented cases with former unsuccessful histological
sampling of the pancreas through alternative
procedures such as endoscopic ultrasound with fine
needle aspiration (EUS-FNA) or endoscopic retrograde
cholangiopancreatography (ERCP).
Procedures
Informed consent was obtained at least 24 h prior to the
intervention after extensive explanation of the method
and its complications. Serum creatinine level, platelet
count, and coagulation values were determined prior to
each intervention. Regarding laboratory cutoff values,
the SIR Guidelines were followed (16).
All interventions were carried out on a 16-row or 128-
row scanner with CT fluoroscopy mode (10–20mAs;
120 kV; Siemens Somatom Sensation 16, Definition
ASþ or Definition Edge, Siemens Healthcare,
Erlangen, Germany). For the planning and control
scan we used the online dose modulation system
(CareDOSE 4D, Siemens Medical Solutions,
Forchheim, Germany) adapting the tube current to the
patients’ anatomy with the ranges of 80–120kV and
100–200mAs.
Anatomical position (head, body, tail), size (diam-
eter in cm), contact of the lesion to macroscopically
visible vessels (celiac artery, superior mesenteric artery
[SMA] and vein, hepatic portal vein, the common hep-
atic artery, and the splenic artery and vein), and best
approach were determined by a biphasic contrast
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enhanced planning CT including an early arterial
(delay, 20 s) and portal venous (delay, 70 s) phase. In
addition, diameter (13–18 G) and length of the true-cut
biopsy system (Magnum, Bard, Murray Hill, NJ, USA)
were chosen (penetration depth, 15 or 22mm). The
patient was positioned depending on the planned
access trajectory (supine, prone left lateral, or right lat-
eral decubitus position).
After skin disinfection, application of 10mL local
anesthesia (2% Scandicain, Astra Zeneca, London,
UK) and sterile draping, the planned entry points
were marked with a 22G fine needle used for applica-
tion of the local anesthesia under CT fluoroscopy. After
skin incision, the true-cut needle was consecutively
inserted to the lesion under intermittent CT fluoros-
copy. One to five true-cut samples were taken using a
sterilizable biopsy gun (Bard Magnum). After formalin
fixation these samples were sent to our local depart-
ment of pathology for histological workup. Five to 10
minutes after the acquisition an unenhanced CT was
obtained to examine the abdomen for active bleeding
or other complications. Duration of the whole proced-
ure was determined by the time period between the
pre-interventional planning CT and the last control
CT (Fig. 1).
Technical and histopathological results
The interventions were defined as primarily technical
successful if at least one histological pancreatic
sample could be obtained. The cases in which type,
tumor grade, and a definitive histopathological diagno-
sis of the lesion could be determined were declared as
diagnostically and clinically successful. Samples includ-
ing no organ tissue or regular pancreatic tissue were
documented. These cases were declared as technically
successful but clinically unsuccessful.
Effective patient radiation dose
For each intervention effective patient radiation dose
was calculated. We summarized the effective dose of
the pre-interventional planning CT, the sum of all
intra-interventional CT fluoroscopic acquisitions, and
the post-interventional CT taken from the CT examin-
ation protocol. Effective patient doses for planning CT
scan and post-interventional control CT scan were cal-
culated using the following formula: E¼DLP * t
(effective dose¼dose-length product * tissue weighting
factor). The tissue weighting factor for the abdominal
region was defined as t¼ 0.0151 (17). The sum of all CT
fluoroscopic acquisitions was evaluated for effective
Fig. 1. CT images of a 69-year-old female patient with an unclear lesion in the pancreatic head; the histological result revealed a G3
adenocarcinoma. (a) Arterial phase of pre-interventional planning scan. (b) Identification of the needle insertion point under CT
fluoroscopic control, by the help of the local anesthesia needle. The white arrow points to the needle. (c) True-cut biopsy under CT
fluoroscopic control by a transhepatic pathway. (d) Non-enhanced post-interventional control scan.
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dose by the adjusted formula for CT fluoroscopy:
E¼DLP * k (k¼ 0.018) according to Spelsberg et al.
(18).
Complications
To assess intra-interventional complications, an inter-
ventional radiologist with more than 10 years of experi-
ence examined all CT images of the procedures. CT
scans were evaluated regarding the needle access trajec-
tory, bleeding, and affected organs. For evaluation of
complications during the 30-day post-interventional
period, patient files were reviewed. Complications
were divided into major and minor according to
Gupta et al. (19).
Statistical analysis
For data collection and statistical analysis, the software
SPSS Version 17.0 (SPSS Inc., Chicago, IL, USA) was
used.
Results
Patient characteristics
One hundred and one consecutive patients (54 women,
47 men) with an unclear pancreatic lesion received a
total of 104 percutaneous CT fluoroscopic-guided
true-cut pancreatic biopsies. Mean age at the interven-
tion was 63.9 12.6 years (age range, 17–90 years).
Mean diameter of the pancreatic lesions in the axial
CT slice was 4.7 2.3 cm (range, 1.5–13 cm). Twenty-
nine (28.7%) patients had undergone an ERCP or
EUS-FNA with unsuccessful tissue sampling before
the CT intervention. Localization of the lesions and
patient characteristics are summarized in Table 1.
Intervention characteristics
One hundred and four interventions were retrospect-
ively analyzed. Access path was ventral (n¼ 60),
dorsal (n¼ 20), left lateral (n¼ 11), and right lateral
(n¼ 11). In 31 cases (30.4%), an access path through
neighboring organs (liver, stomach, and colon) was
chosen. In case of colonic transgression, an antibiotic
with piperacillin/tazobactam was prophylactically
administered pre- and intra-interventionally. In two
cases a transpulmonal pathway was chosen, one of
them intentionally through the lower lobe and the
other one unintentionally through the left pleural
recess. In both cases neither a pneumothorax nor
other pulmonary complication was seen. In the remain-
ing 71 (69.6%) cases a direct access was feasible. Mean
DLP was 810 425 mGy*cm, including the planning
and control CT scan (mean DLP 736 391 mGy*cm)
and the intra-interventional CT fluoroscopy images
(mean DLP 74 72 mGy*cm). Therefore, 89.9 % of
effective patient radiation dose was caused by the plan-
ning and post-interventional control CT scan and
10.1% by intra-interventional CT fluoroscopy.
Mean effective patient dose was 12.5 6.5 mSv,
including effective doses of pre-interventional planning
scan, intra-interventional CT fluoroscopy, and post-
interventional control scan. The intervention character-
istics are summed up in Table 2.
Outcome and complications
Ninety-eight of 104 interventions (94.2%) were technic-
ally successful and a true-cut biopsy could be obtained.
In six cases (5.8%) the intervention had to be stopped
without a successful biopsy, three of them due to
intra-interventional complications (see below). In the
remaining cases reasons were: incompliant patient
(n¼ 1), software problems with the CT scanner
Table 1. Patient characteristics.
Variable
Absolute
numbers
(frequency)
Mean value SD
(range)
Patients (n) 101 (100%)
Gender
- Female 54 (54.5%)
- Male 47 (45.5%)
Age (years) 63.5 12.1
(17–90)
Lesion size (cm) 4.7 2.3
(1.5–13)
Localization
- Head 48 (47.5%)
- Head/Body 8 (7.9%)
- Body 18 (17.8%)
- Body/Tail 5 (5.0%)
- Tail 13 (12.9%)
- Uncinate process 5 (5.0%)
- Entire pancreas 4 (4.0%)
Patients with
pre-interventional ERCP
or EUS- FNA for
unsuccessful sampling
29 (28.7%)
- EUS-FNA 21 (20.8%)
- ERCP 8 (7.9%)
ERCP, endoscopic retrograde cholangiopancreatography; EUS-FNA,
endoscopic ultrasound with fine-needle aspiration.
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(n¼ 1), decision not to perform biopsy due to safety
reasons after evaluation of the planning CT (target
area too close to SMA) (n¼ 1). The primarily unsuc-
cessful interventions could not be attributed to a par-
ticular intervention setting (access path, penetrated
organs, length or needle diameter).
Eighty-eight of the 98 technically successful samples
led to a definitive pathological diagnosis, consistent
with clinical success (89.8%). In the remaining 10 cases
no definitive pathological diagnosis of the lesion could be
obtained. The histopathological results of our patient
cohort are listed in Table 3. Three patients with prior
clinically unsuccessful biopsy received another CT-
guided biopsy, which then led to a successful tissue sam-
pling. The other patients with unsuccessful biopsies
received an ERCP-guided biopsy without successful
tissue sampling (n¼ 1), open surgical biopsy with success-
ful tissue sampling (n¼ 4), or no further biopsy (n¼ 5).
Eighty-two of 104 biopsies (78.9%) were performed
without complications. In 19 of the remaining cases,
minor complications occurred. All cases were minor
self-limiting hematomas evident in the control scan.
None of these complications led to clinical conse-
quences or a longer hospital stay. Additionally, no
case of tumor needle tract seeding was observed
during the 60-day follow-up.
In three patients, major complications related to the
CT-guided intervention occurred:
Patient A (F, 75 years, needle diameter 18 G):
Immediately after needle positioning in the pancreatic
head (lesion diameter of 3.1 cm), a growing opacity of
the mesenteric fat tissue was visible under CT fluoros-
copy. After interruption of the intervention a biphasic
contrast-enhanced CT scan showed a definite bleeding.
The patient was immediately brought to the angiog-
raphy unit where no active bleeding was found. The
patient was moved to the ICU due to a hemoglobin
value drop from 14.1 g/dl to 10 g/dl and packed red
blood cells (PRBC) had to be substituted. One month
after the puncture the patient underwent a successful
Whipple operation. Intraoperatively, a residual hema-
toma (10 6 cm) was found.
Patient B (M, 64 years, needle diameter 18 G) (Fig. 2):
After two samples were successfully taken out of a
lesion (1.5 cm) of the pancreatic head, the post-inter-
ventional control CT scan showed peripancreatic bleed-
ing. The position of the bleeding was subhepatic
extending to the abdominal aortic bifurcation. CT
angiography was immediately performed without
detecting the origin of the bleeding. Maximum size of
the hematoma was 19 10 cm. Eight PRBCs had to be
administered and during the following emergency oper-
ation the underlying bleeding of the epiploic artery
could be controlled.
Patient C (F, 63 years, needle diameter 16 G): Three
samples could be taken successfully out of the pancre-
atic head lesion (5.3 cm). The control CT revealed an
arterial bleeding. In the angiography unit an extrava-
sation out of a side branch of the gastroduodenal artery
(GDA) was detected. Bleeding could be stopped by
selective microcoil embolization (Fig. 2).
Table 2. Intervention characteristics.
Variable
Absolute numbers
(frequency) Mean value SD (range) Mode (range)
Access path
- Ventral 60 (59.0%)
- Dorsal 20 (19.6%)
- Left lateral 11 (10.8%)
- Right lateral 11 (10.8%)
Access path through
- Liver 17 (16.7%)
- Stomach 7 (6.9%)
- Colon 5 (4.9%)
- Lung / Pleural 2 (2.0%)
Needle length (mode) (cm) 13 (10–20)
Needle diameter (mode) (G) 18 (13–18)
Intracorporal length of needle trajectory (cm) 9.6 3.1 cm (3.4–17.7)
Number of samples (mode) 1 (1–5)
Duration of intervention (min) 27.5 8 (14–51)
Total effective patient radiation dose (mSv) 12.5 6.5 (2.0–46.6)
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No correlation between needle diameter and compli-
cations was found.
Post-procedural morbidity and mortality
Due to fast tumor progression, many of the patients
died weeks or months after the diagnosis and the inter-
vention. In the 30-day post-procedural period no
patient had other complications than mentioned
above or died attributable to the intervention.
Discussion
In this study technical and clinical outcome of all CT
fluoroscopy-guided pancreatic true-cut biopsies per-
formed during a 10-year period at our center were
Fig. 2. Images of a 63-year-old woman with an unclear lesion in the pancreatic head. Histological result revealed a mantle cell
lymphoma. (a) Portal-venous phase of pre-interventional planning scan. (b) True-cut biopsy under CT fluoroscopic control with a 16 G
13 cm biopsy system. (c) Contrast-enhanced control scan, the white arrow points on an active arterial bleeding. (d) Angiography, the
white arrow points on an active bleeding from the gastroduodenal artery. (e) Successful embolization with microcoils. (f) Control scan.
Table 3. Histologic results.
n (98)
Definitive histopathologic diagnosis 88 (89.8%)
Adenocarcinoma 63 (64.3%)
Acinar cell carcinoma 1 (1%)
Hepatocellular carcinoma 1 (1%)
Cystadenoma 2 (2%)
Neuroendocrine tumor 6 (6.1%)
Pancreatitis 6 (6.1%)
Lymphoma 5 (5.1%)
Metastases of other tumors 4 (4.1%)
No definitive histopathologic
diagnosis (normal pancreatic tissue)
10 (10.2%)
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investigated. A total of 104 interventions were evalu-
ated; in 88 cases (87%) a definitive histopathological
result and diagnosis could be achieved. Six cases were
technically unsuccessful and in ten cases no final diag-
nosis could be established. Most complications did not
imply any clinical consequences for the patients. In
three cases, major bleeding complications occurred
requiring further treatment.
The high technical and clinical success rates under-
line the high reliability of this procedure.
The clinical importance of this procedure is shown
by the fact that 29 (28.7%) of our patients underwent
CT fluoroscopy-guided intervention after an unsuccess-
ful ERCP-biopsy (8 cases) or EUS-FNA (21 cases).
Otherwise an explorative surgery was the only other
option to obtain a diagnostic specimen.
Former studies about EUS-FNA of pancreatic lesions
have shown an accuracy of 78–95% with a major com-
plication rate of 1.97–2.53% (20). An advantage of
EUS-FNA compared to CT-guided interventions is the
missing radiation exposure to patient and IR (20,21).
However, if the tumor is small or located in the pancre-
atic body or tail, performing EUS-FNA might be prob-
lematic. Another disadvantage of ultrasound guidance is
the poor image quality due to possible intestinal gas
superposition and the required sedation.
ERCP is a diagnostic and a therapeutic procedure
(22). However, the reported accuracy of ERCP-guided
pancreatic biopsies is quite low (46.7%) (7).
Furthermore, the complication rate is higher compared
to other procedures (15.9%) (23). The main complica-
tion of ERCP is post-interventional pancreatitis (5% of
the interventions) which is a severe condition in these
patients and rarely might even be fatal (24).
Additionally, general anesthesia is often required for
complex ERCP procedures.
CT fluoroscopic guidance is characterized by a high
success rate and the potential to reach every pancreatic
region for biopsy. Even an indirect access path travers-
ing other organs can be chosen without severe clinical
consequences. Major vessels covering the lesion can
represent the main clinical limitation. According to
the literature the risk of post-interventional tumor seed-
ing and peritoneal carcinomatosis is not significant in
all three types of procedures (25), and tumor seeding
was not observed in our patient cohort
correspondingly.
A large number of studies have evaluated the value
of interventional CT fluoroscopy guidance in various
anatomic regions (14). Nevertheless, to the best of our
knowledge this is the largest patient series exclusively
undergoing CT fluoroscopy-guided pancreatic true-cut
biopsies. Main advantages of CT fluoroscopy are the
shorter procedure time and lower radiation dose com-
pared to sequential CT guidance (15).
Regarding accuracy, technical and clinical outcome,
our study is in line with other similar studies focusing
on CT-guided pancreatic core biopsies (9,10). The com-
plication rate of CT-guided pancreatic biopsy was 8.7%
reported by Tyng et al. (8) and 2.8% reported by
Paulsen et al. (9), respectively. Our higher complication
rate (21.1%) might be explained by the fact that small
hematomas of no clinical relevance were reported as
minor complications (19). Tyng et al. reported a success
rate of 98.1% (8); in addition, Paulsen et al. reported a
94.4% success rate (9); our slightly lower rate of 89.8%
can be explained by the fact that in our study the inter-
vention was only regarded as clinical successful if not
only tissue sampling but also a definitive histological
result was reached, reflecting the most significant
result for the treatment strategy. Of note, only 63 out
of 88 patients with a definitive histological result were
diagnosed with pancreatic adenocarcinoma (Table 3);
the remaining 25 patients had a wide spectrum of other
pathological diagnoses highlighting the need for histo-
logical confirmation before initiating chemotherapy for
suspected pancreatic cancer.
The main clinical relevant complication of pancre-
atic biopsies is active arterial bleeding. Therefore, prior
to the intervention a biphasic planning CT is manda-
tory to carefully evaluate the needle access path and the
localization of vessels at risk. A post-interventional CT
scan is equally necessary to detect early complications.
Basically in a straightforward intervention an unen-
hanced control scan is sufficient to rule out severe com-
plications. In addition, the procedure has to be
performed by an experienced interventional radiologist
to assure a high quality of the biopsy including a lower
radiation dose compared with non-experienced inter-
ventional radiologists. In this study, up to six different
experienced board-certified interventional radiologist’s
with a minimum of 10 years of experience or a radi-
ology resident in the third year up to fifth year under
the supervision of a board-certified radiologist carried
out the intervention. Equally, a multiprofessional
backup team consisting of surgery, anesthesiology,
and intensive care units is essential in case of major
complications (19).
The main limitation of this study is that all data are
based on a retrospective single-center analysis.
However, as there are clear data that support improved
treatment outcomes for patients with pancreatic cancer
treated at high-volume centers, also the pre-therapeutic
diagnostic procedures should—at least in our opin-
ion—be performed at such specialized cancer centers
with an experienced team of interventional radiologists.
In conclusion, we showed that CT fluoroscopy-
guided pancreatic true-cut biopsy is effective, safe,
and minimally invasive and therefore a reliable alterna-
tive to endosonographic, endoscopic, or surgical tissue
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sampling. This procedure might allow obtaining defini-
tive diagnosis early and thereby shortening the time to
treatment initiation in patients with pancreatic malig-
nancies. Further prospective studies have to define the
exact role and indications for CT-guided true-cut
biopsy compared to alternative invasive, image-
guided, and endoscopic methods.
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